Clinical TrialID 3716

Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients

NCT03376620

Hypertrophic Scar

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
3716
Evidence Id
3716
Core Evidence Id
3716
Source Clinical Trial Id
3688
Herb2 Clinical Trial Id
HBCT003688
Nct Id
NCT03376620
Title
Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients
Status
Completed
Phase
Phase 3
Study Result
No
Study Condition
Hypertrophic Scar
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION
Intervention
DRUG: 1,4-Diaminobutane|DRUG: 10% Urea cream
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Double
Intervention Purpose
Prevention
Gender
Female
Age
Adult, Older_Adult
Enrollment
56
Outcome Measure
Duredness of scar at post treatment time frame for active versus control breast, Surface deformational force in grams of scar tissue in each of the treated breasts, 12 weeks
Sponsor Collaborator
University of Manitoba
Funded By
OTHER
Location
Other Id
B2008:134
Start Date
2011-09-02
Primary Completion Date
2013-08-13
Completion Date
2016-07-15
First Posted
2017-12-18
Results First Posted
Last Update Posted
2017-12-20
Study Document
Study Url
https://clinicaltrials.gov/study/NCT03376620
Title Cn
Title En
Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients
Bilingual Status
semi_complete